This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's What Key Metrics Tell Us About DexCom (DXCM) Q4 Earnings
by Zacks Equity Research
The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
DexCom (DXCM) Misses Q4 Earnings Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of -10% and 0.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
DXCM Q4 Earnings to Reflect Market Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, driving momentum and market expansion into 2025.
Countdown to DexCom (DXCM) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
DexCom (DXCM) Q4 Earnings Preview: What's in the Cards?
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ClearPoint Neuro (CLPT) Surges 22.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
ClearPoint Neuro (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?
by Harshit Gupta
DexCom stock shines with strong fourth quarter and full-year 2024 preliminary results, driven by innovation and global expansion. Explore if it's a buy or hold for your portfolio!
DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook
by Zacks Equity Research
DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.
Alphatec (ATEC) Moves 9.1% Higher: Will This Strength Last?
by Zacks Equity Research
Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?
by Urmimala Biswas
ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.
Sensus Healthcare (SRTS) Surges 7.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Sensus Healthcare (SRTS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Ideas feature highlights: DexCom and Albemarle
by Zacks Equity Research
DexCom and Albemarle are part of the Zacks Investment Ideas article.
DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
DexCom (DXCM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
2025 Picks: 2 Stocks to Buy Now for 50% Upside
by Benjamin Rains
Two S&P 500 stocks--DexCom and Albemarle--are already on sale for investors to buy in 2025.
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
by Zacks Equity Research
Dexcom announces the first Generative AI platform in glucose biosensing.
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada
by Zacks Equity Research
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Integra (IART) Down 1.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DexCom and OURA Ink Partnership for Metabolic Health Innovation
by Zacks Equity Research
DXCM and smart ring maker, OURA, join forces to help individuals make informed decisions regarding diet, exercise and overall well-being.
Here's Why DexCom (DXCM) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
DexCom Q3 Earnings Beat Estimates on Sensor Growth, Stock Rises
by Zacks Equity Research
DXCM's third-quarter 2024 earnings and revenues surpass expectations, fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
DexCom (DXCM) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.